^
    11ms
    A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P1/2, N=5, Active, not recruiting, Beam Therapeutics Inc. | N=102 --> 5
    Enrollment change
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • BEAM-201
    11ms
    A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P1/2, N=102, Active, not recruiting, Beam Therapeutics Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2031 --> Dec 2026 | Trial primary completion date: Dec 2031 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • BEAM-201
    over2years
    A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P1/2, N=102, Recruiting, Beam Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • BEAM-201
    over2years
    A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P1/2, N=102, Not yet recruiting, Beam Therapeutics Inc.
    New P1/2 trial • CAR T-Cell Therapy • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • BEAM-201